Skip to main content

Transmission Raman Spectroscopy for Pharmaceutical Analysis - Insights from Users and Regulators


Obtaining regulatory approval for QC batch release by transmission Raman: Bulk assay, uniformity and identification

  • Dr Julien Villaumié – R&D Senior Scientist, Actavis, UK

Obtaining Regulatory Approval for QC Batch Release by Transmission Raman: Bulk Assay, Uniformity and Identification

Obtaining Regulatory Approval for QC Batch Release by Transmission Raman: Bulk Assay, Uniformity and Identification

Transmission Raman Spectroscopy for CU and Polymorphic Content Determination - Strategy and Approach of J&J

  • Dr Tom van den Kerkhof – Senior Scientist, Janssen, Belgium

Transmission Raman Spectroscopy for CU and Polymorphic Content Determination - Strategy and Approach of J&J

Transmission Raman Spectroscopy for CU and Polymorphic Content Determination - Strategy and Approach of J&J

Quantitative analysis of pharmaceutical bilayer tablets using transmission Raman spectroscopy

  • Dr Gary McGeorge – Senior Principal Scientist, Bristol-Myers Squibb, USA

Quantitative analysis of pharmaceutical bilayer tablets using transmission Raman spectroscopy

Quantitative analysis of pharmaceutical bilayer tablets using transmission Raman spectroscopy

Examples of Transmission Raman Applications at GSK

  • Dr Benoît Igne – Principal Scientist, GSK, USA

Examples of Transmission Raman Applications at GSK

Examples of Transmission Raman Applications at GSK

Transmission Raman spectroscopy (TRS) is an alternative to HPLC for tablet & capsule content uniformity testing and polymorph quantification. Pharmaceutical manufacturers are increasingly using Cobalt's TRS system in R&D and production environments because of the benefits it offers: TRS takes seconds per sample, is robust to sample variation, needs no preparation, solvents or consumables and saves significant cost and resource per batch.

This seminar featured excellent and wide-ranging presentations from experienced TRS users at Bristol-Myers Squibb, Actavis, Janssen, GSK and AbbVie, with a regulatory perspective presented by the UK's MHRA. Many thanks to all our speakers for taking the time to travel and present their work. The event was very popular - we had more interest than spaces at the venue - and feedback suggests there is a high demand for more seminars in the future as the transmission Raman user community rapidly grows.

Obtaining regulatory approval for QC batch release by transmission Raman: Bulk assay, uniformity and identification

  • Dr Julien Villaumié – R&D Senior Scientist, Actavis, UK

Determination of crystallinity in amorphous solid dispersion-based pharmaceutical preparations by means of Transmission Raman-Spectrometry

  • Dr Holger Van Lishaut – Principal Research Scientist, AbbVie, Germany

A review of transmission Raman usage in pharmaceutical R&D at GSK

  • Dr Benoît Igne – Principal Scientist, GSK, USA

The development of transmission Raman spectroscopy for pharmaceutical analysis

  • Professor Pavel Matousek, STFC Senior Fellow & Cobalt Chief Scientific Officer, Rutherford Appleton Labs, UK

Transmission Raman Spectroscopy for CU and Polymorphic Content Determination - Strategy and Approach of J&J

  • Dr Tom van den Kerkhof – Senior Scientist, Janssen, Belgium

Quantitative analysis of pharmaceutical bilayer tablets using transmission Raman spectroscopy

  • Dr Gary McGeorge – Senior Principal Scientist, Bristol-Myers Squibb, USA

Improving your TRS methods: Beam Enhancers and other ideas

  • Dr Andrew Owen – Pharma Product Manager, Cobalt Light Systems, UK

The MHRA's expectations and experiences for spectroscopic methods

  • Dr Abigail Moran - Senior Pharmaceutical Assessor, Medical & Healthcare products Regulatory Agency (MHRA), UK